Navigation Links
Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes

diet and exercise, to improve glycemic control in adult patients with type 2 diabetes who are not adequately controlled on metformin or sitagliptin alone or in patients already being treated with the combination of sitagliptin and metformin. Consistent with the labeling for metformin alone, JANUMET is contraindicated in patients with renal disease, renal dysfunction, or abnormal creatinine clearance; and acute or chronic metabolic acidosis, including diabetic ketoacidosis. JANUMET should not be used in patients with type 1 diabetes. Consistent with the labeling for metformin alone, the labeling for JANUMET contains a boxed warning for lactic acidosis, a rare, but serious, metabolic complication that can occur due to metformin accumulation during treatment with JANUMET.

Initial combination therapy with JANUVIA and metformin significantly improved blood sugar control compared with metformin alone over one year (LB-04; Study #036)

This study demonstrated a mean A1C reduction from baseline of 1.8 percent in patients treated with JANUVIA 50 mg/metformin 1000 mg twice daily for up to 54 weeks (n=153). Additionally, mean A1C reductions from baseline were 1.4 percent in patients treated with JANUVIA 50 mg/metformin 500 mg twice daily (n=147), 1.3 percent in patients treated with metformin 1000 mg twice daily (n=134), 1.0 percent in patients treated with metformin 500 mg twice daily (n=117), and 0.8 percent in patients treated with JANUVIA 100 mg once daily (n=106).

After completing an initial 24-week placebo-controlled phase (n=1091) ("Phase A"), 762 patients with a mean baseline A1C of 8.7 percent continued in a 30-week, double-blind, active-controlled phase ("Phase B") on their previous active treatments: JANUVIA 50 mg/metformin 1000 mg twice daily (n=161); JANUVIA 50 mg/metformin 500 mg twice daily (n=160); metformin 1000 mg twice daily (n=153); metformin 500 mg twice daily (n=147); and JANUVIA 100 mg once-daily (n=141).

Two-thirds (67 percent
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
2. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
5. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
6. Everest Data on Short- and Long-Term Use of Otsukas Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACCs Late Breaking Clinical Trials
7. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
8. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
9. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
10. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
(Date:5/21/2013)...  The North Shore-LIJ Health System is expanding a ... at North Shore University Hospital in Manhasset, ... at Forest Hills (NY) Hospital. ... new pilot program strengthens patient safety by providing hospitals ... first time in the US that remote video auditing ...
(Date:5/21/2013)... -- Vasomedical, Inc. (OTC BB: VASO) (the "Company"), a diversified medical ... medical devices and in the domestic sale of diagnostic imaging ... , President and CEO of Vasomedical, Inc. will present at ... 30, 2013 in New York City ... presentation is scheduled to begin at 9:30 a.m. EDT. ...
(Date:5/21/2013)... BioElectronics Corp. (PINKSHEETS: BIEL), the maker ... that CEO, Andrew J. Whelan ... Advisory Committee, Orthopedic and Rehabilitation Panel compelling arguments ... counter sales. "It,s been 37 years ... schema," Whelan said.  "While the old classification of ...
Breaking Medicine Technology:North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs 2North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs 3North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs 4Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3
(Date:5/21/2013)... , , MONDAY, May 20 (HealthDay News) -- Young drivers ... higher risk of getting into car crashes, but Australian ... sleep on weekends puts them in even greater danger ... another challenge to adolescents that comes with lack of ... of the Center for Injury Research and Prevention at ...
(Date:5/21/2013)... , , MONDAY, May 20 (HealthDay News) -- Long-acting ... chronic obstructive pulmonary disease (COPD) may raise the ... new large Canadian study reveals. The finding ... prescribed long-acting bronchodilators -- either anticholinergics (such as ... are commonly used to relieve the shortness of ...
(Date:5/21/2013)... TUESDAY, May 21 (HealthDay News) -- Thousands of ... from the lung condition known as chronic obstructive ... that patients placed on the common antibiotic azithromycin ... due to flare-ups of the disease. "Given ... of such events is critical," said Victoria Richards, ...
(Date:5/21/2013)... (HealthDay News) -- Racial disparities exist in the treatment ... United States, according to a large new study. ... part of their initial treatment, researchers found that blacks ... surgery in the early stages of the disease. Hispanics ... and stage 2 disease than white patients. "In ...
(Date:5/21/2013)... The surgical management of non-small cell lung cancer ... race of the patient, according to a new study., ... and Stage II NSCLC is surgery," said researcher Jayanth ... Omaha, Nebraska. "In our study of more than 1,200,000 ... years 2000 and 2010, we found statistically significant racial ...
Breaking Medicine News(10 mins):Health News:Weekend 'Catch-Up' Sleep May Cut Young Drivers' Crash Risk 2Health News:Certain COPD Meds Might Raise Heart Risks, Study Says 2Health News:Certain COPD Meds Might Raise Heart Risks, Study Says 3Health News:Long-Term Use of Antibiotic May Help Those With COPD 2Health News:Long-Term Use of Antibiotic May Help Those With COPD 3Health News:Racial Disparities Seen in U.S. Lung Cancer Treatment 2
... The first results of the first European survey of cancer ... 6th congress of the European Federation of Chapters of the ... surveys have looked at the overall management of pain in ... look in detail at Breakthrough Cancer Pain (BTCP) from a ...
... ... Proactive Wellness Centers, PLC -- a leading Anti-Aging Practice, is the featured speaker at ... in Northern Virginia. , ... Sterling, VA (PRWEB) September 11, 2009 -- Most women understand that health factors ...
... ... specialist Flintec has recruited eight new software and electronic developers to ... equipment is Flintec,s fastest growing area of business. Increasing numbers of ... build the precision measuring systems at the heart of their life-saving ...
... , , NEW YORK, Sept. ... and The Mount Sinai Medical Center describe the Community Diabetes ... outreach program which was designed specifically for people from the vulnerable ... Twenty-five patients from The Mount Sinai Medical Center were randomly ...
... , , , ... industry leader, declared his support for H.R. 1891, a House bill ... deduction. Roeser is Senior Vice President of Marketing and Operations for ... -- one of the nation,s largest and most experienced long-term care ...
... , VOORHEES, N.J., Sept. 10 Angioedema is ... organs, and airway, causing discomfort and even death as a result ... the prevention and treatment of angioedema, and new therapies are being ... patient population. , , To address the need ...
Cached Medicine News:Health News:First results from major European patient survey show devastating impact of living with breakthrough cancer pain 2Health News:Dr. Lynese Lawson Speaks to Sterling Women: Strategies to Rejuvenate Your Health and Your Career 2Health News:Dr. Lynese Lawson Speaks to Sterling Women: Strategies to Rejuvenate Your Health and Your Career 3Health News:Flintec Load Cell Design Helps to Create Vital Medical Solutions 2Health News:Flintec Load Cell Design Helps to Create Vital Medical Solutions 3Health News:Flintec Load Cell Design Helps to Create Vital Medical Solutions 4Health News:Dr. Eliscer Guzman, with The Mount Sinai Medical Center, Join Forces to Celebrate the Community Diabetes and Cardiovascular Care Program's Graduation Ceremony on September 16th 2Health News:Industry Leader Praises Health Reform Bill that Provides 50% Tax Deduction for Long-Term Care Premiums 2Health News:New Directions in Angioedema: A Focus on Supportive Care and Treatment Options 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: